TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02877290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation (NIV)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation (NIV)
Study: NCT00436527

Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole gel 1%
Description: Applied once to a test site on the right or left cheek (as determined by a randomization design)
Study: NCT03980327

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Description: Lactobacillus probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: medium chain triglyceride oil
Study: NCT01213355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule, single dose, oral, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: injectable subcutaneous formulation, single dose, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: 5 mg, PF-05212377, capsule, single dose, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: injectable subcutaneous formulation, single dose, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: 20 mg, capsule PF-05212377, single dose, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scopolamine
Description: injectable subcutaneous formulation, single dose, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212377
Description: 60 mg PF-05212377, capsule, single dose, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scopolamine
Description: injectable sub cutaneous formulation, single dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Tablet, 10mg, single dose, 1 day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: injectable sub cutaneous formulation, single dose, 1 day
Study: NCT00894465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Children are randomized to receive oral midazolam .5 mg/kg prior to undergoing VCUG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Children are randomized to receive a placebo prior to undergoing VCUG
Study: NCT03056352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Intravenous medication drip

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Intravenous medication drip
Study: NCT01375010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2000 mg QD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Supplements
Description: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin Supplements
Description: Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).
Study: NCT00637442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reminyl retard
Description: retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
Study: NCT03214458

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal high flow
Description: The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases/
Study: NCT01743677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Single dose 100 mg (5 x 20 mg tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose placebo tablets (5 tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single dose Avelox 400 mg tablet
Study: NCT02436135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablets administered orally for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablets administered orally for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablets administered orally for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib tablets administered orally for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered per standard of care according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered per standard of care according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered per standard of care according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered per standard of care according to package insert
Study: NCT02063698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: auranofin
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study: NCT01750775

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo Capsule
Description: placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
Study: NCT01441024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: 20 mg per day of DAS181-FO3 for 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg per day of Lactose for 5 days
Study: NCT02063698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT02122211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine supplement
Study: NCT01740492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.15mg/kg
Description: 0.15mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
Study: NCT04378725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based smoking prevention and cessation program (The KOTAK program)
Description: Advance Intervention: Following the screening process, this intervention package was inclusive of group-briefing for the smokers in at least 3 subsequent sessions in one academic year. The content delivered by the dentist were based on the KOTAK guidebook consisted of 8 Modules.The modules were as follows:~1. Introduction: Identifying students who smoke~2. Cigarette and addiction~3. The danger of smoking and passive smokers~4. Advantages of smoke-free lifestyle and adolescent perception on smoking~5. Legal and religious perception of smoking~6. The benefits of smoking cessation~7. Preparation and how to stop smoking~8. Nicotine withdrawal symptom and relapse prevention~The Intervention schools: Screened smokers were given Advanced Intervention sessions. After discussion with the State's oral health deputy director and district's programme coordinator, for the purpose of this study, the interval of the Advance Intervention session was decided at 1-month interval.
Study: NCT02182492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin 250 mg tablet once daily for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Description: Fluticasone propionate nasal spray 200 μg/d for 3 months
Study: NCT01740492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.3mg/kg
Description: 0.3 mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
Study: NCT00476684

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency treatment
Description: Radiofrequency-neurotomy of the medial branch at 80 degr. C needle temperature for 70 seconds, after diagnostic blocks
Study: NCT00620477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection in the knee joint with 20 ml of chirocaine 0.125%
Description: injection in the knee joint with 20 ml of chirocaine 0.125%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: injection in the knee joint with 20 ml of physiological fluid
Description: injection in the knee joint with 20 ml of physiological fluid
Study: NCT02544906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Infusion of propofol to prevent emergence agitation in liver transplanta recipients
Study: NCT00476684

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham neurotomy
Description: Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
Study: NCT02544906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomedine
Description: Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
Study: NCT02616094

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1
Description: The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1
Description: The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1
Description: The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
Study: NCT02085707

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip replacement arthroplasty
Description: treatment with total hip replacement arthroplasty with the implant chosen by the institution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed reduction and internal fixation
Description: treatment with closed reduction and internal fixation with 2 cannulated hip pins
Study: NCT02783742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication coaching
Description: Study coaches will conduct tailored individual sessions with participating providers to teach and improve communication techniques. Coaches will then shadow or audio-record patient encounters and deliver feedback to providers on their communication during these encounters.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Communication coaching
Description: Study coaches will conduct tailored individual sessions with participating providers to teach and improve communication techniques. Coaches will then shadow or audio-record patient encounters and deliver feedback to providers on their communication during these encounters.
Study: NCT02567435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT02616094

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2
Description: The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2
Description: The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2\*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
Study: NCT03021226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatherhood Development
Description: Fatherhood Development is a curriculum based program provided by a facilitator through a skill-based education intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relationship Enhancement
Description: Relationship Enhancement is a curriculum based program provided by a facilitator through a skill-based education intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Literacy
Description: Relationship Enhancement is a curriculum based program provided by a facilitator through skill-based education intervention.
Study: NCT01452269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deaf Weight Wise program
Description: Groups will consist of approximately 13 subjects who meet for 2 hours a week for 16 weeks. Group sessions will be offered at a variety of times and days of the week. A trained, deaf, ASL-fluent counselor will lead the sessions.~Subjects will be asked to complete a food and physical activity diary. Each intervention session will include a weigh-in, group sharing/problem solving, discussion of a weight management topic, and goal setting/action planning for the next week. Periodically, each subject will receive a Personal Feedback Report. Subjects will be able to earn points for complying with various aspects of the program. Points can be redeemed for small prizes (i.e. water bottles).~The maintenance phase consists of two meetings at the beginning of the 6-month maintenance period and three months later. This will consist of a weigh-in, review of self-monitored diet and physical activity, problem solving and goal setting/action planning for their long-term program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deaf Weight Wise program
Description: Groups will consist of approximately 13 subjects who meet for 2 hours a week for 16 weeks. Group sessions will be offered at a variety of times and days of the week. A trained, deaf, ASL-fluent counselor will lead the sessions.~Subjects will be asked to complete a food and physical activity diary. Each intervention session will include a weigh-in, group sharing/problem solving, discussion of a weight management topic, and goal setting/action planning for the next week. Periodically, each subject will receive a Personal Feedback Report. Subjects will be able to earn points for complying with various aspects of the program. Points can be redeemed for small prizes (i.e. water bottles).~The maintenance phase consists of two meetings at the beginning of the 6-month maintenance period and three months later. This will consist of a weigh-in, review of self-monitored diet and physical activity, problem solving and goal setting/action planning for their long-term program.
Study: NCT02567435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT06462001

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guerin Vaccine Intravesical
Description: BCG (Oncotice) is administered intravesically as per usual standard of care

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin Vaccine Intravesical
Description: BCG (Oncotice) is administered intravesically as per usual standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: MMC is administered intravesically as per usual standard of care
Study: NCT01633749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza subunit vaccine Influvac
Description: 3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
Study: NCT00736333

Intervention type: DRUG
Intervention: Pegylated Liposomal Doxorubicin
Description: Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m\^2, given for up to 6 cycles
Study: NCT00899288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spectroscopy
Description: Nails will be chemically characterized using Raman spectroscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spectroscopy
Description: Nails will be chemically characterized using Raman spectroscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spectroscopy
Description: Nails will be chemically characterized using Raman spectroscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spectroscopy
Description: Nails will be chemically characterized using Raman spectroscopy.
Study: NCT04423653

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth home exercise program
Description: The intervention will include videos of exercises and also live coaching using telehealth system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth home exercise program
Description: The intervention will include videos of exercises and also live coaching using telehealth system.
Study: NCT01481831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron Hydrochloride
Description: 0.25 mg IV\*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron Hydrochloride
Description: 0.25 mg IV\*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron Hydrochloride
Description: 0.25mg IV\*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron Hydrochloride
Description: 0.25mg IV\*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
Study: NCT02856997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide with ICE regimen
Description: Chidamide and ICE regimen, dosage described in arm description
Study: NCT01498419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (M)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (M)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (M)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomid (Pa)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomid (Pa)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomid (Pa)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (Z)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (Z)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide (Z)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour
Description: Rifafour e-275 once daily for 8 weeks. Daily dose dependent on weight as follows: 30-37kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets: 71 kg and over: 5 tablets
Study: NCT02182258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 soft gelatine capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBF 1120 intravenous solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ampoule
Study: NCT04549909

Intervention type: OTHER
Intervention: collect retrospectively data
Description: Analyse the incidence of BPL in these populations

Intervention type: OTHER
Intervention: collect retrospectively data
Description: Analyse the incidence of BPL in these populations

Intervention type: OTHER
Intervention: collect retrospectively data
Description: Analyse the incidence of BPL in these populations

Intervention type: OTHER
Intervention: collect retrospectively data
Description: Analyse the incidence of BPL in these populations
Study: NCT03768219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: APVO210
Description: APVO210
Study: NCT03490552

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: mechanical thrombectomy
Description: Mechanical thrombectomy whatever it type ( SRT , ASPT or Mixed )will be used to extract the thrombi from stroke causing occlusion to be preserved biologically for genomic lab. transfer to be processed by RNA sequencing analysis technique for identifying markers for its composition pointing to its source.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mechanical thrombectomy
Description: Mechanical thrombectomy whatever it type ( SRT , ASPT or Mixed )will be used to extract the thrombi from stroke causing occlusion to be preserved biologically for genomic lab. transfer to be processed by RNA sequencing analysis technique for identifying markers for its composition pointing to its source.